Skip to main content

Novel Rx

ICYMI: JAKi in inflammatory myositis? #ACR24 will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis… https://t.co/8XOYOsDsD4 https://t.co/MF0EGO0BJz
Dr. John Cush @RheumNow( View Tweet )
Tocilizumab Efficacy in Giant Cell Arteritis Phenotypes A Spanish Collaborative Group study of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA) demonstrated high efficacy regardless of the different vascular phenotypes treated. https://t.co/nwCU3qW4PT https://t.co/uhvFDrW5Zz
Dr. John Cush @RheumNow( View Tweet )
Biosimilars Do Impact Biologic Drug Costs Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these products -- even though biosimilars… https://t.co/UoVMc3lSxR https://t.co/A8Sl9bzvla
Dr. John Cush @RheumNow( View Tweet )
3 biosimilars from Celltrion have received a positive recommendatoin from the CHMP of the EMA for pt), Stoboclo and Osenvelt (denosumab biosimilars), and Avtozma (tocilizumab biosimilar), possibly redefining treatment affordability and accessibility across Europe.… https://t.co/dYXfUSpP5I https://t.co/wLQMXomoVS
Dr. John Cush @RheumNow( View Tweet )
ICYMI: Are Emulation Trials a Fantasy? https://t.co/eCO8a1UFlB https://t.co/PPczmxYFKa
Dr. John Cush @RheumNow( View Tweet )

Abuse of the Safety-Net 340B Drug Programs

Dr. Madelaine Feldman has written an important commentary on the 340B Drug Pricing Program, a safety-net program that would allow vulnerable populations to receive expensive new therapies. But she points out that "this well-intentioned program has strayed from its original purpose", allowing

Read Article
Efficacy and Safety of Nipocalimab for Sjogren's Syndrome Dr. Mike Putman reports on abstract 2527, Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled,… https://t.co/kkIOCUZRml https://t.co/nL47c5veCp
Dr. John Cush @RheumNow( View Tweet )

Tocilizumab Efficacy in Giant Cell Arteritis Phenotypes

A Spanish Collaborative Group study of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA) demonstrated high efficacy regardless of the different vascular phenotypes treated. 

Multicentre study of 471 GCA patients treated with TCZ, assessed outcomes according to vascular

Read Article

Biosimilars Do Impact Biologic Drug Costs

MedPage Today

Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these products -- even though biosimilars barely dented Humira prescription rates.

Read Article

ICYMI: Sex related differences in PsA

Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and safety of treatments as well as outcomes

Read Article

ICYMI: Are Emulation Trials a Fantasy?

Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?

Read Article
Bimekizumab in PsA Showed Sustained Reductions in Disease Impact Dr. Eric Dein talks with Dr. Ana-Marie Orbai about abstract 0600, Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis… https://t.co/HiqIly6Kii https://t.co/sFyqHE6ug1
Dr. John Cush @RheumNow( View Tweet )
Small, suspended, post COVID randomized trial, guselkumab failed to show efficacy at reducing proteinuria in 33 SLE pts. Wk24 results, 56% placebo vs. 35% GUS for primary end point., No differences in secondary outcomes or adverse events https://t.co/27imkXkbUn https://t.co/yGdDQlu5v3
Dr. John Cush @RheumNow( View Tweet )

ICYMI: GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis

A retrospective cohort study presented at #ACR24 explores the benefits of GLP-1Ras in reducing the risk of end-stage renal disease (ESRD) for patients with lupus nephritis. Drawing on data from the TrinetX global research database, the study examines how GLP-1Ras may reduce ESRD progression in a

Read Article
Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/SMKx1LnBB1 https://t.co/96u5YuvyIf
Dr. John Cush @RheumNow( View Tweet )
Ozempic will change rheumatology @drdavidliew Ozempic is everywhere. Even all the way in Australia, where we have highly constrained supply that makes headlines and substantial limits on direct-to-consumer advertising, somehow I know the jingle from the American ad for Ozempic.… https://t.co/4gujykjDCa https://t.co/RLG1vA57kC
Dr. John Cush @RheumNow( View Tweet )
Novel TYK2 inhibitor Zasocitinib Interest in tyrosine kinase 2 (TYK2), a member of the JAK family, is growing following the success of JAK inhibitors in treating rheumatic diseases. TYK2 is crucial for immune activation but has minimal involvement in metabolic and hematopoietic… https://t.co/KbHcgSIohv https://t.co/0g8X4zrq4X
Dr. John Cush @RheumNow( View Tweet )
FDA has granted Rare Pediatric Disease Designation (RPDD) to a new proprietary investigational drug, 101-PCG-005, a type IA prodrug of dexamethasone targetsing CD206+ macrophages. The intended use is in systemic juvenile idiopathic arthritis (sJIA) or Still's disease .… https://t.co/ErNWlva9Nd https://t.co/gc8cPNs3H1
Dr. John Cush @RheumNow( View Tweet )
Inebilizumab for Treatment of IgG4-Related Disease Inebilizumab is a monoclonal antibody that depletes CD19+ B cells and has been studied in adults with IgG4-related disease. In a phase 3, double-blind, randomized, placebo-controlled trial, it reduced IgG4-related disease… https://t.co/7PAmCn9O2I https://t.co/NmNA1p6GmI
Dr. John Cush @RheumNow( View Tweet )
Phase 2b Study of Ianalumab in Sjögren's A 52-week has demonstrated the safety and efficacy of ianalumab, a dual B cell depleter) in patients with active Sjögren's disease (SjD). https://t.co/08W0N1f3ap https://t.co/lyZwGI56Qq
Dr. John Cush @RheumNow( View Tweet )

Don’t Buy Guitars (12.6.2024)

This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.

Read Article

Inebilizumab for Treatment of IgG4-Related Disease

Inebilizumab is an monoclonal antibody that targets and depletes CD19+ B cells and has been studied in adults with IgG4-related disease. A phase 3, double-blind, randomized, placebo-controlled trial, and was shown to reduce IgG4-related disease
Read Article

Phase 2b Study of Ianalumab in Sjögren's

A 52-week has demonstrated the safety and efficacy of ianalumab, a dual B cell depleter) in patients with active Sjögren's disease (SjD).

The Phase 2b trial enrolled 190 SjD patients who were randomized (1:1:1:1) to either placebo or ianalumab (5, 50, or

Read Article
Off-Label Use of JAK Inhibitors in Orphan Diseases and Other Conditions? The issues surrounding publication bias are real. https://t.co/gIFNjAsoM6 https://t.co/UstQGvJX7H
Dr. John Cush @RheumNow( View Tweet )
J&J has submitted 2 supplemental BLAs applying for FDA approval of guselkumab( Tremfya) for use in juvenile plaque psoriasis & juvenile (>5-6 yrs age) psoriatic arthritis based on several phase 3 RCTs. https://t.co/dAkH219pzN https://t.co/R9yJCSOVJa
Dr. John Cush @RheumNow( View Tweet )
×